Melvin Rivera

Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma

J. Lee, J. Heymach, D. Gibbons, 2022, Cancers.

Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified

J. Lee, F. Meric-Bernstam, B. Esmaeli, 2021, Cancer.

Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

A. Tsao, D. Gibbons, F. Fossella, 2021, JCO precision oncology.

Relationship of Staff Engagement and Perception of Safety Scores with Patient Outcomes

S. Cheong, Rosalina Butao, Melvin Rivera, 2018 .